Simulations Plus Joins European SimInhale Consortium
September 26 2016 - 8:30AM
Business Wire
EU Framework Programme (Horizon 2020) for
Acceleration of New Inhaled Medicines
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of
modeling and simulation software for pharmaceutical discovery and
development, today announced that it has been accepted into the
SimInhale COST (European Cooperation in Science and Technology)
Action, a consortium composed of approximately 100 current
university, research institute, and industry members from across
Europe.
As one of only two U.S. participants, Simulations Plus will
participate in activities designed to:
- advance particle designs for improved
deposition and interaction with lung tissue
- promote realistic computer simulations
of particle aerosolization, delivery and deposition
- promote patient-tailored inhaled
medicines
- promote integration of device and
formulation design
- promote critical assessment of toxicity
issues and related risks
SimInhale will establish a roadmap to realistic computer
simulations that will provide quantitative data to designers of
aerosolized medicines and inhalation devices. Simulations Plus was
invited to join SimInhale because of its state-of-the-art Pulmonary
Compartmental Absorption and Transit (PCAT™) Module in its
industry-leading GastroPlus™ physiologically based pharmacokinetics
(PBPK) software program. Simulations Plus scientists will
participate in several Working Groups within SimInhale.
John DiBella, vice president for marketing and sales for
Simulations Plus, said, “Our acceptance into this prestigious group
validates our expertise with aerosolization, and gives us the
opportunity to work directly with the outstanding members of
SimInhale for the advancement of simulation technology for inhaled
medicines. We will participate as full members with access to data
and expertise that will help us to improve our pulmonary model to
better serve industry, regulatory agencies, and academia in this
important area.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking
drug discovery and development software, which is licensed to and
used in the conduct of drug research by major pharmaceutical and
biotechnology companies worldwide. The company is a global leader
focused on improving the ways scientists use knowledge and data to
predict the properties and outcomes of pharmaceutical and
biotechnology agents. Our innovations in integrating new and
existing science in medicinal chemistry, computational chemistry,
pharmaceutical science, biology, and physiology into our software
have made us the leading software provider for physiologically
based pharmacokinetic modeling and simulation as well as a leading
provider of both preclinical and clinical pharmacometric consulting
services for regulatory submissions. For more information, visit
our website at www.simulations-plus.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160926005319/en/
Simulations Plus Investor
RelationsMs. Renee
Bouche661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron
Donahue651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Sep 2023 to Sep 2024